Evidence map›Paper›PMID 28825720›Full record

ArticleOncogenesis2017

MicroRNA-34a/EGFR axis plays pivotal roles in lung tumorigenesis.

Y-L Li, X-M Liu, C-Y Zhang, J-B Zhou, Y Shao, C Liang, H-M Wang, Z-Y Hua, S-D Lu, Z-L Ma

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogenesis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 63 citations in OpenAlex.

  1. Melatonin in lung cancer: integrating molecular mechanisms, tumor microenvironment regulation, apoptotic signaling, and therapeutic opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Prospects of microRNAs as therapeutic biomarkers in non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2023
    Review
  8. Review
  9. Review
  10. Heliyon · 2023
    Review
  11. Article
  12. Article
  13. The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer.International journal of molecular sciences · 2022
    Review
  14. Article
  15. Article
  16. Article
  17. miR-199a-5p Plays a Pivotal Role on Wound Healing via SuppressingOxidative medicine and cellular longevity · 2022
    Article
  18. Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.International journal of molecular sciences · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Y-L LiLab for Noncoding RNA &Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
X-M LiuLab for Noncoding RNA &Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
C-Y ZhangLab for Noncoding RNA &Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
J-B ZhouLab for Noncoding RNA &Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
Y ShaoLab for Noncoding RNA &Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
C LiangLab for Noncoding RNA &Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
H-M WangLab for Noncoding RNA &Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
Z-Y HuaLab for Noncoding RNA &Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
S-D LuShanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China.
Z-L MaLab for Noncoding RNA &Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
Shanghai University · CNShanghai Sixth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are vital in the regulation of tumor progression and invasion. Dysregulation of miRNAs has been linked to the development of various types of human cancers, including non-small-cell lung cancer (NSCLC). However, the effect of miRNA-34a (miR-34a), a key regulator of tumor suppression, on the tumorigenesis of NSCLC has not been fully elaborated. Herein, we reveal that miR-34a is significantly downregulated in NSCLC tissues and cell lines, suggesting that miR-34a might function as a tumor suppressor in lung cancer. We also confirmed that epidermal growth factor receptor (EGFR) is a direct target of miR-34a, and our data reveal that siRNA knockdown of EGFR can inhibit cell proliferation, promote apoptosis and arrest cell-cycle progression. In addition, EGFR can reverse the suppressive function of miR-34a overexpression on proliferation and cell apoptosis. Furthermore, in vivo experiments demonstrated that miR-34a suppress tumor growth, both in the A549 xenograft model, as well as in the metastatic tumors in nude mice. Taken together, our findings suggest that miR-34a inhibits NSCLC tumor growth and metastasis through targeting EGFR.

Identifiers

PMID28825720
PMCPMC5608916
OpenAlexW2745712870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.